|
|
|
글쓴이 : 해준송효
날짜 : 25-06-21
조회 : 17
|
|
|
| 제목 : 바다이야기동영상 48.rge117.top 슬롯종류 |
|
| |
 http://35.rfm813.top (4) | | http://9.rsk311.top (4) |
|
릴게임갓 90.rge117.top 바로가기 성인오락황금성, 무료 슬롯 메타
체리마스터 릴게임바다이야기 기프트 전환무료야마토황금성 슬롯
황금성게임랜드 93.rge117.top 상품권릴게임
릴게임 무료충전게임 74.rge117.top 야마토무료게임
야마토5게임다운로드 26.rge117.top jQuery 슬롯 머신
바다이야기 꽁머니 환전 윈윈 88.rge117.top 알라딘릴게임 사이트
오션파라다이스게임하는법 25.rge117.top 온라인슬롯머신
바다이야기 슬롯 20.rge117.top 릴게임연타
pc릴게임 63.rge117.top 릴황금성
온라인야마토릴게임 91.rge117.top 오리지날게임
메이저 슬롯사이트 44.rge117.top 동영상황금성
체리마스터 공략 37.rge117.top 바다이야기다운로드
바다이야기릴게임 온라인삼국지 일본야마토 바다이야기 게임 다운로드 최신릴게임 릴게임백경 777 잭팟 럭키세븐 릴게임알라딘주소 몰게임 릴게임매장 도그하우스 하는법 강원랜드 슬롯 잘 터지는 기계 릴게임임대 온라인릴게임 무료신천지게임 백경 릴게임신천지사이트 릴게임골드몽사이트 야마토하는곳 양귀비 바다슬롯 먹튀 최신야마토게임 강원랜드 슬롯머신 하는법 매장판 성인릴게임 릴게임사이다 무료백경 릴신천지 카카오바다이야기 바다이야기황금고래 바다이야기공략법 바다이야기 릴게임 사이트 추천 및 안내 야마토무료게임 릴게임오션 릴게임황금성 바다이야기노무현 바다이야기게임공략방법 오션파라다이스다운로드 야마토게임무료다운받기 슬롯머신 무료게임 오션파라다이스예시 릴박스 황금성예시 모바일바다이야기 강원랜드슬롯머신 알라딘릴게임장 바다이야기 무료체험 카지노 슬롯 게임 추천 야마토오락 실게임 온라인 슬롯 배팅법 릴게임 사이트 오션바다이야기게임 야마토5게임공략법 야마토게임 방법 인터넷게임사이트 무료온라인게임 검증완료릴게임 야마토3게임다운로드후기 릴게임오션파라다이스 릴게임 신천지 알라딘예시 야마토2 pc버전 블랙잭하는법 바다이야기 환전 보물섬릴게임 오락실황금성 백경예시 황금성릴게임 무료슬롯머신777 바다이야기게임다운 바다이야기게임다운로드 슬롯머신 신천지 게임 공략법 알라딘게임공략법 바다이야기apk 무료슬롯 얌얌 파친코 무료인터넷바다이야기 무료야마토릴게임 바다이야기 노무현 황금성온라인 카지노 잭팟 오리지날야마토 무료야마토 꽁머니사이트 백경게임 다운로드 야마토2게임 바다이야기꽁머니환전 온라인야마토주소 사이다쿨게임 릴게임 코리아 10원야 마토 릴게임황금성오션바다 10원야 마토 꽁머니 고전릴게임 우주전함야마토게임 오션파라 다이스게임 하는법 바다이야기7 체리마스터 릴게임 바다이야기게임다운 백경다운로드 릴게임손오공하는법 슬롯버그 릴게임종류 릴게임 신천지사이트 바다이야기 무료 슬롯게임 실시간 바다이야기환전가능 무료충전게임 성인놀이터 최신야마토게임 슬롯 머신 html 바다이야기 황금고래 다빈치무료릴게임 릴게임갓 오리지날릴게임 바다신게임 온라인 슬롯 머신 게임 슬롯 머신 이기는 방법 무료릴게임 무료충전야마토 모바일파칭코 온라인 릴게임 This article was released as Pharm Edaily Premium Content on June 19, 2025, at 8:34 AM.
[이데일리 김새미 기자] In the Korean bio-healthcare sector on the 18th, shares of Shin Poong Pharm., Co. Ltd and its preferred stock surged to the daily upper limit for a second consecutive day, buoyed by news of a European patent for its COVID-19-related drug ‘Pyramax’ and concerns over황금성 릴게임
a resurgence of COVID-19. Geninus and Viol also posted gains of over 10%.
Shinpoong Pharm: Two-Day Surge on European Patent for Pyramax
According to KG Zeroin’s MP Doctor (formerl펀드운용사
y Market Point), shares of Shinpoong Pharm closed at 16,650 KRW, up 3,840 KRW (29.93%) from the previous day. The company’s preferred stock also hit the upper limit, rising 10,700 KRW (29.93%) to 46,4주식재야고수
50 KRW.
Top Gainers on the KOSPI Market on the 18th (Source=KG Zeroin MP Doctor)
The surge follows the June 골드몽게임
16 announcement that Pyramax, Shinpoong’s anti-malarial drug, had secured a European patent for the prevention or treatment of epidemic RNA virus infections, including COVID-19. The European Patent Of동일방직 주식
fice (EPO) granted the patent for the drug’s pharmaceutical composition.
The rally coincides with a regional resurgence of COVID-19 in parts of Asia. Although no significant increase has yet been observed in South Korea, health authorities remain cautious. In the 22nd week of 2025 (May 25?31), the number of COVID-19 inpatients at 221 domestic hospitals remained around 105, maintaining the weekly average of about 100. Viral detection rates, which had been declining since March, began climbing again around the 20th week (May 11?17), stabilizing around 8%.
Last summer, COVID-19 cases in Korea climbed from 456 in late July to 1,441 by mid-August. With case numbers rising in countries like China, Thailand, and Taiwan, experts warn that Korea cannot afford complacency. The Korea Disease Control and Prevention Agency (KDCA) recently predicted that domestic cases may increase again in late June.
However, industry insiders urged caution about investor optimism. One pharmaceutical insider commented, “A patent can be granted even at the lab stage and is unrelated to its effectiveness in humans,” adding, “Even global players like Pfizer are facing poor sales of COVID-19 treatments and vaccines, and it’s unclear whether there’s sufficient demand for new COVID-19 therapeutics.”
Geninus Gains 18.9% on Korean Big Pharma Contract
Geninus shares closed up 18.94% after a pay-to-read PharmEdaily article fueled investor interest. At 2:15 PM, PharmEdaily published a piece titled: “Geninus Secures Deal With a Major Pharma... Revenue Set to Soar 2.4x.” Trading volume rose sharply, and shares ended the session at 2,700 KRW.
Geninus Stock Trend on the 18th (Source=KG Zeroin MP Doctor)
According to the article, Geninus signed a contract with a leading Korean pharmaceutical firm to provide AI-powered genome analysis services. Industry speculation strongly points to a specific company, widely believed to be a global biosimilar leader.
Sources suggest Geninus’ cutting-edge technology was key to landing the deal, particularly as the pharma partner embarks on an ADC (antibody-drug conjugate) project. Geninus’ proprietary platform is seen as essential for ADC development.
Geninus has developed “Intellimed,” a simulation solution for ADC drug development. It performs single-cell analysis and spatial mapping to understand cellular positioning―crucial for precision medicine including immuno-oncology, ADCs, and bispecific antibodies.
Revenue expectations for Geninus are rising. The initial contract is worth around 500 million KRW, but the full deal may reach several billion KRW. Given Geninus’ 2024 revenue of 6.5 billion KRW, this represents a substantial boost. Additional contracts with a global pharma company and a major domestic player are reportedly imminent.
A Geninus spokesperson stated, “Geninus has been significantly undervalued, so this upward trend could continue. Although we cannot disclose the partner or full contract value, it’s true the deal has been signed.”
Viol Rallies on PEF Tender Offer: “K-Beauty’s Global Appeal Evident”
Viol surged on news that private equity firm VIG Partners had launched a tender offer with the goal of voluntarily delisting the company. Shares closed at 12,380 KRW, up 1,180 KRW (10.54%).
VIG’s SPC, Vienna Investment Company, announced it would buy up to 37,438,265 shares?64.09% of Viol’s outstanding stock?at 12,500 KRW per share by July 7. If successful, VIG would hold 98.84% of Viol.
The plan is to delist Viol and turn it into a fully-owned private subsidiary. However, if less than 12,125,998 shares (20.76%) are tendered, the buyback will be canceled.
This isn’t the first time a medical aesthetic device maker in Korea has gone private via a PEF tender offer. In June 2023, Lutronic Corp. was acquired by Hahn & Company and delisted by October. Similarly, French PEF ArchiMed acquired Jeisys Medical Inc. and pursued delisting in November 2023.
An industry insider noted, “Korea’s aesthetic medical device makers have long been attractive targets due to their high profitability. Viol joining the ranks of delisted firms affirms K-beauty’s global popularity, though retail investors may lament the loss of a promising investment opportunity.”
김새미 (bird@edaily.co.kr)
|
|
|
|
|
|
|
|
|
